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Abstract
Introduction: revious work reported the anti-arthritic synergy afforded by combining calcitonin (CT) and glucocorticoids
(GC). Here we focus on the pairing of elcatonin (eCT) and dexamethasone (Dex), querying whether: i) this was a class-effect
action; ii) mechanistic insights could be unveiled; iii) the synergy affected canonical GC adverse effects.
Methods: Using the rat collagen-induced arthritis model, different combinations of eCT and Dex, were administered from
disease onset to peak (day 11 to 18). Macroscopic disease score was monitored throughout, with biochemical and
histological analyses conducted on plasma and tissues at day 18. The effect on acute hyperglycaemia and liver enzyme
message were also assessed.
Results: Whilst eCT alone was inactive, it synergised at 1 mg/kg with low doses of Dex (7.5 or 15 mg/kg) to yield an anti-
arthritic efficacy equivalent to a 4- to 7-fold higher Dex dose. Mechanistically, the anti-arthritic synergy corresponded to a
marked attenuation in RA-relevant analytes. CXCL5 expression, in both plasma and joint, was markedly inhibited by the co-
therapy. Finally, co-administration of eCT did not exacerbate metrics of GC adverse effects, and rescued some of them.
Conclusions: We present evidence of a class-effect action for the anti-arthritic synergy of CT/GC combination, underpinned
by the powerful inhibition of joint destruction markers. Furthermore, we identify CXCL5 as a marker for the combination
therapy with potential diagnostic and prognostic utility. Substantial GC dose reduction, together with the absence of
exacerbated adverse effects, indicated a significant clinical potential for this co-therapy in RA and beyond.
Citation: Al-Kashi A, Montero-Melendez T, Moradi-Bidhendi N, Gilligan JP, Mehta N, et al. (2013) The Calcitonin and Glucocorticoids Combination: Mechanistic
Insights into Their Class–Effect Synergy in Experimental Arthritis. PLoS ONE 8(2): e54299. doi:10.1371/journal.pone.0054299
Editor: John Wallace, McMaster University, Canada
Received November 6, 2012; Accepted December 10, 2012; Published February 5, 2013
Copyright:  2013 Al-Kashi et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was funded by a collaborative project between Unigene Corporation and Queen Mary University of London and, in part, by The William
Harvey Research Foundation. The authors could operate freely in design the experiments, analyse data and prepare the manuscript. The funders had no role in
study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have read the Journal’s policy and have the following details on conflicts of interest: Adam Al-kashi – no competing interests
to declare. Trinidad Montero-Melendez – no competing interests to declare. Niloufar Moradi – no competing interests to declare. Jim Gilligan – Employee of Tarsa
Pharmaceutical that has developed oral calcitonin. Nozer Mehta – Employee of Unigene Corporation, that produce calcitonin for nasal administration. Mauro
Perretti: ‘‘declared that he is one inventor (out of three in total; the other two are Dr Lucia Mancini and the deceased Prof I McIntyre) of a patent held by Queen
Mary and Westfield College (legal identify of Queen Mary University of London). The details are as follows: European Patent Application No. 06726589.2 Queen
Mary & Westfield College Use of calcitonin as a combined treatment therapy for the management of inflammatory disease conditions the authors confirm that
this does not alter their adherence to all the PLOS ONE policies on sharing data and materials. The novel study under assessment by PLOS ONE represents a
scientific extension of a previous one (Mancini L et al., Am J Pathol 2007; PMID: 17322385) [ref 20 in the manuscript] onto which the patent application is based
(original PCT application in UK, 1st April 2005; initial application to EU, 30th March 2006).’’ The competing interests declared here do not alter the authors’
adherence to PLOS ONE policies on sharing data and materials.
* E-mail: m.perretti@qmul.ac.uk
Introduction
Glucocorticoids (GCs) are fundamental therapeutics in the
treatment of inflammatory diseases. Their clinical benefits derive
from a complex spectrum of effects downstream of GC receptor
(GR) activation, which serves to modulate several thousand genes
amounting to ,1% of the genome [1]. This results in the down-
regulation of many pro-inflammatory mediators [2,3] and up-
regulation of anti-inflammatory and pro-resolving factors [2].
However, these benefits come at a price: a veritable catalogue of
adverse effects, particularly evident upon mid- to long-term
administration. Amongst the more severe of these are hypergly-
caemia, osteoporosis and hypertension [4–6]. Despite these
adverse effects, the use of GCs in the treatment of inflammatory
diseases has remained widespread. The juxtaposition between
benefit and detriment justifies pre-clinical efforts to identify better
treatment regimens.
There has been a significant research effort focused on the
development of GCs exhibiting an improved pharmacological
profile, retaining anti-inflammatory efficacy with reduced adverse
effects [7]. Selective GR agonists or ‘dissociated’ steroids may offer
a more pronounced transrepression over transactivation, resulting
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in fewer adverse effects [8]. Unfortunately, despite early optimism
[9], dissociated steroids have thus far failed to translate smoothly
from preclinical to clinical investigations [10], and, since
transactivation of anti-inflammatory and pro-resolving factors
represents a relevant part of GC efficacy [11], it is perhaps of little
wonder. In recent years, a modified-release prednisone formula-
tion has demonstrated significantly increased efficacy in the
attenuation of RA morning stiffness, without changing the safety
profile [12]. Previous pharmacokinetic strategies have included the
use of alternate routes of administration to avoid systemic
exposure [13] and the development of shorter half-life GCs with
a similar aim [14]. Low-dose GC therapy appears to provide a
degree of benefit with only modest adverse effects [15], and the
recent EULAR recommendations for cardiovascular risk manage-
ment in RA patients support the approach of minimal dose for
minimal duration [16]. However, reducing exposure, and
consequent efficacy, in a bid to avoid adverse effects serves as an
apt reminder of our failure to adequately separate GC-induced
benefit from GC-induced harm.
Calcitonin (CT) is a 32-amino acid peptide secreted by the
parafollicular cells of the mammalian thyroid, and by the
ultimobrachial body of many lower vertebrates. It was discovered
in 1961 as a hypocalcaemic hormone [17], and mechanistic
insights soon followed, with observations of increased urinary
calcium and reduced urinary hydroxyproline (a bone resorption
marker) [18]. The anti-resorptive effect was soon exploited
therapeutically in the treatment of bone metabolic disorders
[19], and is now understood to involve a direct effect upon the
osteoclast, blocking reactivity to several activators, including
RANKL and GC [20,21]. CT can exert a direct protective effect
on chondrocytes, enhancing collagen and proteoglycan synthesis
with beneficial implications for diseases involving cartilage
degradation [22,23]. It also displays modulatory functions on
other RA-relevant cells, including osteoblasts [24] and perhaps
synoviocytes [25]. Decades on from its discovery, CT is a standard
therapeutic option for Paget’s disease of the bone, and also
effective against post-menopausal- and GC-induced osteoporosis
[26], but its near exclusive identification with bone protection
belies under-exploited potentials, particularly in anti-inflammation
and analgesia.
Anti-inflammatory effects for CT have been demonstrated in a
number of animal models, including adjuvant-induced arthritis
[27], though not in collagen-induced arthritis [28]. Human
lymphocytes express CT receptors which are regulated by IL-1
and IL-6 [29], suggesting an immunomodulatory role, and CT
treatment in vitro has been found to reduce intracellular and
secreted IL-1a/b in leukocytes from RA patients [30].
Collagen-induced arthritis (CIA) in the rat shares many
similarities with human RA, including synovial hyperplasia,
immune cell infiltration and marginal bone erosions [31]. Unlike
the adjuvant-induced model, which is associated with non-relevant
extra-articular manifestations, CIA also results in the generation of
rheumatoid factor [31–32]. Using the rat CIA model, we
previously reported that the co-administration of salmon CT
and prednisolone produced an unexpected anti-arthritic syner-
gism, affording GC dose reduction [20]. The applicability of this
co-treatment to other GCs, as well as the molecular mechanisms
that underlie these synergies, were not clarified. The present study
was undertaken in order to broaden our knowledge of the CT/GC
combination. Particular emphases were placed on further char-
acterisation, mechanistic inquiry and a survey of classical GC
adverse effects. We have expanded the previous molecule-specific
observations to a class effect action through the use of an alternate
CT/GC pairing, namely elcatonin (eCT) and dexamethasone
(Dex), and propose the clinical testing of this synergy.
Materials and Methods
Materials were purchased from Sigma-Aldrich Co. (Poole, UK)
unless otherwise specified. Elcatonin (eCT) was purchased from
Bachem UK Ltd. (Merseyside, UK). Bovine nasal collagen-II (CII)
was purified in-house from source material.
Collagen-induced Arthritis
Female Lewis rats (150620 g body weight; Harlan UK Ltd.,
Bicester, UK) were fed a standard chow pellet and water diet ad
libitum, and maintained on a 12-hour light/dark cycle. Animal
work was conducted under license from the Home Office and in
accordance with the Animals (Scientific Procedures) Act, 1986.
Bovine CII was dissolved in acetic acid (0.01 M) at 4 mg/ml
and emulsified in an equal volume of complete Freund’s adjuvant
(CFA). On day 0, rats were anaesthetized with isoflurane and then
injected intradermally with 200 ml of the CII/CFA emulsion
(400 mg of collagen-II per rat) at the base of the tail. Elcatonin was
dissolved in PBS with 0.1% bovine serum albumin (BSA). Dex was
pre-solubilised in dimethyl sulphoxide (DMSO) prior to diluting in
PBS with 0.1% BSA (final DMSO concentration was less than
0.05% and considered negligible). Elcatonin, Dex and combina-
tions thereof were given daily by intraperitoneal injection from day
11 (typical arthritis onset) onwards. Routinely, groups of 8 rats for
each treatment were used (range from 7 to 10). Hind paw volume
measurements were quantified by water displacement (Ugo Basile,
Milan, Italy) whilst clinical scores were recorded using a three-
point scale of anatomical region involvement, with ankle, pad and
digits each contributing one point (giving a maximum score of 6).
On day 18 (or day 21 in preliminary experiments), animals were
killed by cervical dislocation and blood was collected by cardiac
puncture on to heparin (50 U/ml of blood; Leo Pharma,
Buckinghamshire, UK) and plasma prepared by centrifugation.
Hind paws, liver tissue and plasma aliquots were stored at 280uC
unless being processed for immediate analyses.
Histological Processing and Assessment
Hind paws were fixed overnight in 4% neutral buffered
paraformaldehyde, decalcified for 7–10 days in 30% formic acid
with 0.5M trisodium citrate, and embedded in paraffin. Longitu-
dinal sections (5 mm) were cut from the centre of the ankle joint in
the sagittal plane and stained with haematoxylin-eosin. Sections
were examined by light microscopy for cellular infiltration,
synovitis, bone erosion and structural integrity.
Preparation of Paw Tissue Extracts
Hind paws were homogenized whole (Wet n’ Dry Grinder,
Revel, Houston, Texas) in 5 ml PBS with 1% Triton X100 and
protease inhibitors (complete EDTA-free protease inhibitor
tablets; Roche Diagnostics, West Sussex, UK). After 1-hour
incubation at room temperature, supernatants were collected by
centrifugation. Samples were normalised by total protein concen-
tration (BCA protein assay; Thermo Scientific Pierce, Loughbor-
ough, UK).
Immunochemical Assays
The following markers were assayed using commercially
available kits: MMP-2, CXCL5, CCL5, CCL20, CXCL7 ELISA
from R&D Systems (Abingdon, UK); telopeptide of type-I collagen
(CTX-I) EIA from Immunodiagnostic Systems (Tyne & Wear,
UK); TRAP-5b and ACTH EIA from Biosupply UK Ltd.
CT/GC in Joint Disease
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(Bradford, UK). Circulating levels of serum amyloid protein A
(SAA) were quantified by ELISA (TSZ ELISA, Framingham,
Maryland, USA). Proteome profiling was performed by rat
cytokine array kit from R&D Systems.
Assessment of GC Induced Off-target Side Effects
Rats (routinely 8 animals per treatment) were fasted for 14 h
and then given a single dose of Dex (15 or 100 mg/kg i.p.) with or
without 1.0 mg/kg eCT. Blood was collected by venepuncture and
glucose was quantified immediately prior to fasting, prior to drug
treatment, and 5 h after drug treatment by Accu-Chek meter
(Roche Diagnostics, West Sussex, UK). Blood was then collected
by cardiac puncture on to EDTA (2 mM) for adrenocorticotropin
(ACTH) assay, and animals were killed by cervical dislocation.
Liver tissue was collected and stored at 280uC.
Quantitative real-time PCR was performed in liver tissue from
the CIA and hyperglycaemia experiments (routinely 4 samples per
treatment were analysed). RNA was extracted using the RNeasy
Mini Plus Kit from Qiagen UK Ltd. (Crawley, UK). cDNA was
synthesized using 1-mg of total RNA with the SuperScript III
Reverse Transcriptase (Invitrogen, Paisley UK). Real time-PCR
was performed with 200-ng of cDNA per well and Power SYBR
Green PCR Master Mix (Applied Biosystems, Warrington, UK),
using the ABI Prism 7900HT Sequence Detection System, and
commercially available primers for tyrosine aminotransferase (Tat;
QT00182308), phosphoenolpyruvate carboxykinase (Pck2;
QT01825327), glucose-6-phosphatase (G6pc3; QT00190610)
and fructose-1,6-bisphosphase (Fbp2, QT01791076); all from
Qiagen UK Ltd. Glyceraldehyde 3-phosphate dehydrogenase
mRNA (Gapdh, QT00199633) was used as internal control. Data
was expressed as 22DDCt, where DCt = Ct of the target gene
(e.g.Tat) – Ct of the internal control gene (Gapdh), and
DDCt =DCt of the samples for target gene – DCt of the calibrator
(control group) for the target gene.
Statistics
Data are presented as mean 6 SEM of n number of rats. Data
analyses were conducted by one-way ANOVA comprising
Kruskal-Wallis test and Dunn’s post-test for multiple comparisons,
or by Mann-Whitney U test for single comparisons; both with an
alpha value of p.0.05.
Results
Rat CIA is Highly Sensitive to Dex
Paw volume data, pooled from twelve separate experiments,
clearly illustrates the time course of the CIA reaction (Figure 1A),
with mean onset at day 11 and mean peak at day 18. Clinical
scores displayed an identical time course when viewed across the
entire study (Figure 1B). Disease incidence for this protocol was
,100% at the reaction peak (Figure S1). Dex is potently anti-
arthritic in the rat CIA model, with abrogation of paw swelling
and clinical score at the 100 mg/kg dose given from day 11
onwards (Figure 1C/D). Sub-therapeutic and moderately thera-
peutic doses of 7.5 and 30 mg/kg, respectively, were used in
subsequent experiments.
Elcatonin Affords GC Dose Reduction Through Anti-
arthritic Synergy
The synergistic CT-GC interaction has been evidenced
previously in this lab, using salmon calcitonin and prednisolone
in the rat CIA model [20]. One of the aims of this present study
was to expand this agent-specific observation to a class-effect one.
Thus, having characterised the efficacy of Dex, we next
endeavoured to find the optimal eCT dose for co-administration,
testing the 0.3–10 mg/kg range, given daily from day 11. Figure S2
depicts a representative time-course experiment. The result was an
inverse bell-shaped relationship that centred on the optimal dose
of 1.0 mg/kg eCT (Figure 1E). The combination of sub-
therapeutic Dex (7.5 mg/kg) with eCT resulted in approximate
68% attenuation of clinical score, which was not significantly
different from the 75% attenuation achieved by 30 mg/kg Dex
(Figure 1D). Thus, this synergy affords a 4-fold Dex dose
reduction.
We then undertook one further step of co-treatment optimisa-
tion by testing a ‘borderline’ therapeutic dose of Dex (15 mg/kg).
Co-therapy with eCT (1.0 mg/kg) from day 11 resulted in
abolition of clinical score presentation, akin to a 7-fold higher
dose of Dex alone (Figure 1F).
Histological Analysis Correlates to Macroscopic Efficacy
Microscopic examination of the tarsal region revealed a clear
distinction between therapeutic and non-therapeutic regimens.
Joints from vehicle-treated animals showed intense cellular
infiltration and synovitis with focal bone erosions and distorted
joint architecture (not shown), which was left unchanged by either
eCT or sub-therapeutic Dex alone (Figure 2A, B). In contrast, the
co-therapy regimen left structurally joints intact with minimal or
no infiltrate (Figure 2C), in line with what observed with full dose
Dex monotherapy (Figure 2D), which yield a histological image
not distinguishable from that of naı¨ve joints.
Biochemical Markers in Tissue and Plasma
Having established and optimised drug doses for the co-
treatment, we next investigated the biochemical correlates of the
anti-arthritic efficacy, starting with classical markers. Analysis of
total matrix metalloproteinase (MMP)-2 levels in hind paw tissue
extracts revealed a significant attenuation by the co-administration
of eCT with sub-therapeutic Dex, but not by the individual
therapies alone (Figure 3A). Meanwhile, serum C-terminal cross-
linking telopeptide of type-I collagen (CTX-I) – a classical
circulating and urinary marker of bone resorption [33] – was
significantly reduced from 24.262.0 ng/ml in vehicle-treated
animals to 12.463.7 and 11.162.3 ng/ml in animals given eCT
alone or with sub-therapeutic Dex, respectively (n = 7 to 14;
P,0.01 in either case), i.e. displaying no synergism. Plasma
TRAP-5b more than doubled in rat CIA compared to the plasma
of naı¨ve counterparts (Figure 3B). This pathology-associated
elevation in TRAP-5b was significantly reduced in the co-therapy
treated animals, but not in those receiving either eCT or sub-
therapeutic Dex alone (Figure 3B).
The above markers are known to be associated with joint
disease/cells and clearly their modulation by eCT 6 Dex is of
importance. In order to expand the field of knowledge, we
employed a proteome-profiling assay to screen for unpredicted
markers for the co-therapy. The dot blot-like cytokine assay was
run on joints extracts yielding several semi-quantitative hits (Figure
S3). Four chemokines were taken forward for precise quantifica-
tion, however for three of them we did not observe significant
modulation, namely CCL5, CCL20 or CXCL7 (Figure S4). In
contrast, tissue CXCL5 was reduced by 64% in response to the
CT/GC co-therapy (Figure 3C). Analysis of plasma CXCL5
revealed that circulating levels of this chemokine are increased in
arthritic rats, compared to naı¨ve animals, and that this increase is
abolished by the co-therapy (Figure 3D). Both for tissue and
plasma CXCL5 values, low dose Dex or eCT alone were inactive,
whilst significant reduction were attained by the co-therapy.
CT/GC in Joint Disease
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Figure 1. Elcatonin synergises with Dexamethasone in the rat CIA model. (A, B) Time course of CIA in rats. Collagen was given at Day 0 and
arthritis developed from Day 11 and peaked at Day 18, as measured by paw oedema volume (A) and clinical score (B). Data, mean 6 SEM, are
cumulative of twelve CIA experiments (n = 76 to 82 rats, except for day 21 where n= 16). (C, D) In separate experiments, at first signs of disease (Day
11), vehicle or Dexamethasone (Dex) were given daily i.p. with powerful inhibition of hind paw oedema (C) and clinical score (D), as shown for peak
response at Day 18. Data are mean 6 SEM (n = 4 to 8 rats). (E) Having established the glucocorticoid dose response, a sub-therapeutic dose of
Dexamethasone (7.5 mg/kg) was combined with elcatonin (eCT; 0–10 mg/kg) – given i.p. from Day 11 - revealing an anti-arthritic synergy, shown here
at peak with Day 18 values. Treatment with elcatonin (1 mg/kg) alone is alone shown (eCT). Data are mean 6 SEM of 10 rats. (F) Co-administration of
1.0 mg/kg eCT shifts Dexamethasone dose-response curve to the left (both compounds given from i.p. from Day 11), enabling abolition of clinical
score presentation with an 85% lower dose, see Dex 15 mg/kg versus 100 mg/kg (all values are from peak, Day 18). Data are mean 6 SEM of 10
animals. In all cases, statistical analyses by one-way ANOVA (Kruskal-Wallis test with Dunn’s post-test); *p,0.05, **p,0.01, and ***p,0.001 as
compared to vehicle-treated group (dose 0).
doi:10.1371/journal.pone.0054299.g001
CT/GC in Joint Disease
PLOS ONE | www.plosone.org 4 February 2013 | Volume 8 | Issue 2 | e54299
Circulating levels of SAA were also measured, observing a
,25% reduction in the Dex (7.5 mg/kg group) compared to
vehicle-treated arthritic rats (38046266 vs. 49166195 U/ml;
n = 8; P,0.05). This effect was not altered by the co-treatment
with eCT (1 mg/kg; SAA values of 37666246; not significant from
Dex alone).
Assessing the Impact of eCT Co-administration on
Classical GC Adverse Effects
In light of the profound therapeutic enhancement afforded by
eCT co-administration, it became relevant to assess if the co-
therapy also augmented classical GC adverse effects.
Elcatonin co-administration was assessed using a protocol of
acute GC-induced hyperglycaemia. Rats were fasted overnight
prior to receiving a single dose of Dex with or without eCT. Blood
glucose was assessed for hyperglycaemia after five hours. As
reported above (Figure 1F), the optimal co-therapy was as
efficacious as high-dose Dex (100 mg/kg) in suppressing clinical
score presentation. However, whilst high-dose Dex induced
hyperglycaemia, neither the optimal co-therapy nor its constitu-
ents alone, altered blood glucose significantly (Figure 4A).
Furthermore, we found that eCT (1.0 mg/kg) co-administration
reduced high-dose Dex-induced hyperglycaemia by 48%
(Figure 4A).
In line with the hyperglycemia data, eCT did not worsen the
suppression of blood ACTH levels produced by Dex, actually
trending towards attenuation, irrespective of whether it was used
at a sub-therapeutic (15 mg/kg) or fully therapeutic (100 mg/kg)
dose (Figure 4B).
Liver samples were collected from the animals used in the
hyperglycaemia protocol to monitor modulation of genes coding
for gluconeogenesis-related enzymes. There were several changes
in mean values, however only the reduction of Tat mRNA by
high-dose Dex was significant (Figure 5A). Importantly, eCT did
not significantly alter mRNA levels, and co-administration had no
significant impact upon Dex-induced changes (Figure 5A to D).
Liver samples from CIA experiments were also used for
gluconeogenesis enzyme message quantification. Analysis was
performed on ‘efficacy bands’ comprising treatment groups paired
by their therapeutic outcome; i.e. the ‘moderate efficacy band’
comprises [Dex 30 mg/kg] and [Dex 7.5 mg/kg+eCT 1.0 mg/kg]
regimens which collectively achieve ,70% clinical score reduc-
tion, whilst the ‘high efficacy band’ comprises [Dex 100 mg/kg]
and [Dex 15 mg/kg+eCT 1.0 mg/kg] which afford ,100%
efficacy. Three key observations arose from this analysis. Elcatonin
alone significantly increases Tat mRNA in the CIA context (Figure
S5A). In the high efficacy band, the co-therapy results in a
significantly greater level of mRNA for Tat, Pck2 and G6pc3
(Figure S5A to C). Fbp2 exhibited a markedly different pattern to
the other three targets. Dex, in the context of rat CIA, increases
Fbp2 gene transcription in a dose-dependent manner. The co-
therapy abolished elevations of Fbp2 mRNA in the moderate and
high efficacy bands (Figure S5D).
Discussion
With this study we report a series of in vivo and ex vivo analyses
to reveal the biological properties of the eCT/Dex combination.
Together with our previous report on salmon CT and prednis-
Figure 2. Combination of elcatonin and sub-therapeutic Dexamethasone preserves articular integrity. Day 18 CIA rat hind paws from
rats treated with collagen at Day 0. Elcatonin (eCT) and Dexamethasone (Dex) were given i.p. daily from Day 11, as detailed in Legend to Figure 1.
Paws were fixed, de-calcified, paraffin-embedded, sectioned and stained with haematoxylin-eosin. Light micrographs (representative of 4 animals),
showing synovitis, cellular infiltrate, bone erosion and articular integrity. (A) eCT 1.0 mg/kg alone, (B) Dex 7.5 mg/kg alone, (C) co-treatment: eCT
1.0 mg/kg+Dex 7.5 mg/kg, (D) Dex 30 mg/kg. Scale bar, 300 mm.
doi:10.1371/journal.pone.0054299.g002
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olone [20], these new data support the existence of a class-effect
CT/GC synergism. Importantly, we pinpointed specific effectors
of the synergism, with CXCL5 identified as a novel potential
marker for this anti-inflammatory treatment in both tissue and
plasma. Collectively, these preclinical analyses provide the rational
for testing a GC and a CT preparation as a novel co-therapy for
chronic human inflammatory pathologies.
A major aim of this study was to characterise an optimal CT/
GC combination. Elcatonin alone was not therapeutic in rat CIA,
confirming previous data with salmon CT [20] and making this
model of arthritis ideal for stretching the co-therapy to its limit of
efficacy. We found this limit to lie at the intersection between
15 mg/kg Dex and 1.0 mg/kg eCT, which afforded an abolition of
clinical score presentation with an 85% GC dose reduction.
Equally, a combination therapy of 7.5 mg/kg Dex and 1.0 mg/kg
eCT, given daily from disease onset, produced an effect similar to
that attained by a four-fold higher dose of Dex. It should be noted
that a tight therapeutic window emerged with respect to the eCT
dose and the synergistic outcome, with the dose of 1 mg/kg eCT
giving consistent synergy throughout the study.
The integrity of the joint in the animals treated with the effective
co-therapy, evident at the macroscopic level, was confirmed
histologically, with a clear absence of pannus formation, very low
degree of immune cell infiltrates into the synovial tissue and virtual
absence of erosion into the cartilage/bone. The latter effect is
reminiscent of the effects of salmon CT [20] and could be
corroborated by the negative modulation afforded by eCT alone
on circulating CTX-I. TRAP-5b is a marker of osteoclast number,
rather than osteoclast activity [34], with both diagnostic and
prognostic applications in osteoporosis and other diseases involv-
ing bone resorption [35]. It is worth noting that MMP-2 is secreted
by cultured rheumatoid synovial fibroblasts [36], and is elevated in
the synovial fluid and serum of RA patients [37,38]. Synergistic
modulation of these two players associated with articular disease
Figure 3. The combination elcatonin/Dexamethasone elicits a synergistic attenuation of MMP-2, TRAP-5b and CXCL5 expression.
Rats were treated with collagen on Day 0 and then, from Day 11, received daily i.p. injections of elcatonin (eCT; 1.0 mg/kg) alone or together with a
sub-therapeutic dose of Dexamethasone (D; 7.5 mg/kg) (Co-Tx, combination therapy). A positive control group of rats was treated with
Dexamethasone (30 mg/kg). In all cases hind paw tissue extracts and plasma samples were taken at day 18. Protein levels of (A) metalloproteinase II
(MMP-2) in tissue extracts, (B) plasma tartrate-resistant acid phosphatase (TRAP-5b), (C) tissue extract and (D) plasma CXCL5 were determined as
described in Methods. Data are mean 6 SEM of 10 rats per group. Statistical analyses by one-way ANOVA (Kruskal-Wallis test with Dunn’s post-test);
*p,0.05, **p,0.01, and ***p,0.001 as compared to vehicle-treated group.
doi:10.1371/journal.pone.0054299.g003
CT/GC in Joint Disease
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provides mechanistic support to the therapeutic potential of the
co-therapy here proposed.
Equally important observations could be evinced from the
protein array. Whilst the dot blot array indicated a few false
positives, as revealed by quantitative and specific ELISA
determinations, the identification of CXCL5 may become of
great importance. This CXC chemokine is secreted by RA
synoviocytes and accounts for ,40% of the neutrophil chemoat-
tractant capacity of RA synovial fluid in vitro [39]. In addition, in
co-culture assays, synovial fibroblasts release CXCL5 which is
then exposed on endothelial cells to attract immune cells [40].
Several studies have linked GCs to CXCL5 attenuation [41–43]
and, indeed, this chemokine was first identified as an LPS-induced
GC-attenuated response gene product [44]. No literature to our
knowledge directly relates CXCL5 to CT.
In view of the biological properties of CXCL5, its reduction in
the joint extracts provides a novel mechanism of action for the co-
therapy; however, of equally great importance is the evident
synergism for reduction in circulating CXCL5 with the co-
treatment Dex 7.5 mg/kg+eCT 1.0 mg/kg, giving values in
arthritic rats similar to those of non-arthritic naı¨ve animals.
Altogether, these data prompt us to propose that inhibition of
CXCL5 generation in the joint may be one of the mechanistic
effectors of the synergism, and its modulation in the circulation
could be exploited as a reliable biomarker for the clinical
development of the co-therapy.
In the final part of the study we addressed the important issue of
side effects: would the co-therapy result in a synergistic augmen-
tation of canonical side effects characteristic of GC therapeutic
use? The acute administration of eCT together with low-dose Dex
had no effect on changes in glycaemia (in fasting rats) and
circulating ACTH indicating that CT does not synergise with the
glucocorticoid in relation to these outcomes; in contrast, at full
dosage of Dex, eCT seems to attenuate, and certainly not to
augment, these side effects.
Affirmatively, eCT co-administration did not alter acute Dex-
induced modulation of liver enzymes, and, when comparing
regimens by their anti-arthritic efficacy, eCT effectively abolished
the Dex-induced elevation of liver F-1,6-BP mRNA in CIA.
However, more intriguing were the results obtained for the
expression of the other liver enzymes in CIA. When plotted
against efficacy, Tat mRNA assessed in liver tissue from CIA rats
treated with the co-therapy versus Dex alone revealed an
intersection between apparent bell-shaped and inverse bell-shaped
profiles (Figure S5A). Elcatonin significantly increased Tat
message alone or in combination with 15 ug/kg Dex, but not
with 7.5 ug/kg Dex. The Pck2 and G6pc3 data also partially
support this indication (Figure S5B, C). This finding is, of course,
not entirely surprising since CT alone can induce hepatic
gluconeogenesis [45–47]. The important point to be made here
is that neither agent alone is the magic bullet. Any ‘magic’ is to be
found in a truly optimised combination. Our data supports the
assertion that an appropriately optimised CT/GC synergism
appears to be specific to the desirable therapeutic effects in the
context of experimental arthritis.
GCs have presented us with one of medicine’s truly canonical
perplexities. Their clinical utility renders these agents indispens-
able, yet the severity of adverse effects cannot be disregarded. An
awareness of both their benefits and risks has been accumulating in
the literature since the 1950’s. Since then, voluminous efforts to
separate benefit from risk, via pharmacokinetic and dissociation
strategies, have not afforded established clinical translation. Thus,
there has long been, and remains, a pressing need for an adequate
solution. An NO-donor GC analogue (‘nitro-steroid’) has been
found to offer an enhanced anti-inflammatory and anti-arthritic
effect in rodent models [48], while preventing GC-induced
hypertension [49]; and a prednisolone/dipyridamole combination
also provides greater anti-inflammatory effect in acute and chronic
models, with reduced GC-induced HPA axis suppression and Tat
induction [50] – a combination which is currently in phase II
development for RA.
Figure 4. Elcatonin does not augment Dexamethasone-induced hyperglycaemia and ACTH suppression. Fasted rats were given a single
dose of Dexamethasone (15 or 100 mg/kg i.p.) with or without 1.0 mg/kg elcatonin (eCT). Blood was collected by venepuncture and glucose was
quantified: i) immediately prior to fasting, ii) prior to drug treatment, and iii) 5 h after drug treatment. Overnight fasting caused a fall in mean blood
glucose from 6.1960.10 to 4.8060.13 mM. Blood glucose in the vehicle-treated group continued to drop, reaching 3.8660.22 mM at the 5-hour time
point. (A) Blood glucose data as measured 5 h post-treatment, and normalised for differing pre-fasting levels. (B) ACTH was assayed by EIA in blood
collected by terminal cardiac puncture at 5 h post-treatment. ACTH suppression is expressed in relation to the levels quantified by ELISA in vehicle-
treated animals (1.5760.09 ng/ml). In both panels, data are mean 6 SEM of 8 rats per group. Statistical analyses by one-way ANOVA (Kruskal-Wallis
test with Dunn’s post-test); *p,0.05, **p,0.01, and ***p,0.001 as compared to vehicle-treated group, or by Mann-Whitney test; {p.0.05 in the
indicated comparison.
doi:10.1371/journal.pone.0054299.g004
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Conclusions
Therapeutic GC doses bring the burden of unwanted side
effects as a consequence of broad genomic effects, and countering
efforts have prioritised the dissection of this reality, to rescue the
strengths from the weaknesses. However, it is our assertion that the
true strength of GCs lies within this apparent weakness. GCs may
be particularly amenable to co-therapeutic synergy by virtue of
their broad genomodulatory action – recasting them as a minefield
of latent synergies. The combination of low- and even sub-
therapeutic GC doses with suitable candidates can afford
enhanced therapeutic effect. Optimally these co-therapies also
bring a diminution of the classical GC adverse effects, either
indirectly via a dose reduction of the GC, or via a directly effect of
the co-therapy agent. Thus our recommendations are two-fold,
that our evidence warrants clinical development of the CT/GC
co-therapy and that our evidence be taken as a call for a
generalised transition of thought regarding the optimal utility of
GC agents. It is our belief, that by transitioning from a magic
bullet monotherapy paradigm to an arguably more elegant
harnessing of latent synergy potentials we can finally, not solve
the GC ‘problem’, but transcend it.
Supporting Information
Figure S1 Collagen-induced arthritis in the female
Lewis rat reaches 100% incidence. Mean6SEM percentage
incidence as assessed by positive clinical score presentation across
twelve separate experiments (n = 76 to 82, except for day 21 where
n = 16).
(TIF)
Figure S2 Elcatonin synergises with Dex in the rat CIA
model. Time course of exemplary CIA experiment in rats treated
with collagen on day 0. At the first signs of disease (Day 11),
vehicle, Dexamethasone (7.5 mg/kg) or Dexamethasone plus the
reported doses of Elcatonin were given daily i.p.; clinical score was
monitored for a further week up to Day 18. Data are mean6SEM
(n = 7 rats per group).
(TIF)
Figure 5. Elcatonin co-administration does not augment Dexamethasone-induced changes in gluconeogenesis-related liver
enzyme mRNA. Quantitative real time-PCR was performed in liver tissues harvested from the hyperglycaemia experiment (see Legend to Figure 4
for protocol), in which fasted rats received single dosing of Dexamethasone (mg/kg) with or without elcatonin (eCT; 1.0 mg/kg). The expression of the
following genes was studied: (A) tyrosine aminotransferase (Tat); (B) phosphoenolpyruvate carboxykinase (Pck2); (C) glucose-6-phosphatase (G6pc3);
(D) fructose-1,6-bisphosphase (Fbp2). Data was expressed as 22DDCt using Gapdh as endogenous control. Values report mean 6 SEM of 4 distinct rat
samples. Statistical analyses by one-way ANOVA (Kruskal-Wallis test with Dunn’s post-test); *p,0.05, ns p.0.05 as compared to vehicle-treated
group.
doi:10.1371/journal.pone.0054299.g005
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Figure S3 Cytokine proteome profiler indicates poten-
tial markers in tissue extracts. (a) Profile from pooled
vehicle-treated group, n = 7. (b) Profile from pooled co-therapy
(eCT 1.0 mg/kg+Dex 7.5 mg/kg) group, n = 7. Legend grid
highlights analytes of greater expression.
(TIF)
Figure S4 CCL5, CCL20 and CXCL7 are not markers of
anti-arthritic treatment. (a) CCL5, (b) CCL20 and (c)
CXCL7 in paw tissue extracts from day 18 as determined by
ELISA. Levels are expressed as Mean6SEM analyte mass per
milligram of total protein. Co-Tx denotes the combination of Dex
7.5 mg/kg and eCT 1.0 mg/kg. (n = 6 to 14).
(TIF)
Figure S5 The effect of eCT co-administration on Dex-
induced liver enzyme message in the CIA model. RNA
extraction and RT-PCR was performed using liver tissue from the
CIA protocol (see Legend to Figure 1), harvested on day 18. Data
are mean6SEM 2eDDCt of 4 rats for (A) TAT, (B) PEPCK, (C)
G-6-P and (D) F-1,6,BP plotted against the efficacy of each
regimen (% clinical score reduction). Statistical analyses by Mann-
Whitney test; *p,0.05 in single comparisons between regimens
paired by efficacy band (anti-arthritic effect of: 0%, 65–75% and
90–100%).
(TIF)
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